The FDA approval was based on data from a randomized, multi-arm, controlled clinical trial (n=1,879) that showed using Tegaderm CHG IV Securement Dressing lowered CRBSI by 60% in patients with ...

This evidence includes a randomized controlled trial of 1,879 subjects that found Tegaderm CHG I.V. Securement Dressing reduced CRBSI by 60 percent in patients with central and arterial lines (p=0 ...

To address the growing concern of PIV complications, 3M has introduced 3M™ Tegaderm™ Antimicrobial I.V. Advanced Securement Dressing and 3M™ Tegaderm™ Antimicrobial Transparent Dressing to ...

Tegaderm ® application was associated with significantly lower daily weight loss throughout the first week of life (P=0.04; data not shown). TEG infants also regained their birth weight faster ...